6IB Stock Chart & Stats
€9.80
-€0.10(-2.36%)
At close: 4:00 PM EST
€9.80
-€0.10(-2.36%)
Day’s Range― - ―
52-Week Range€7.91 - €11.70
Previous CloseN/A
Volume0.00
Average Volume (3M)532.00
Market Cap
€16.79B
Enterprise Value€97.38B
Total Cash (Recent Filing)€18.24B
Total Debt (Recent Filing)€2.82B
Price to Earnings (P/E)163.1
Beta0.22
Next Earnings
Aug 26, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding1,740,920,800
10 Day Avg. Volume172
30 Day Avg. Volume532
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.71Price Target Upside39.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.15
Revenue Forecast (FY)€2.07B
Bulls Say, Bears Say
Bulls Say
Commercialization Platform In ChinaAn in-house commercialization platform focused on hospital channels gives Innovent durable revenue reach and control over market access in China. Persistent sales capabilities support product rollouts, pricing negotiations, and capture of hospital demand across oncology and autoimmune franchises over the next 2–6 months and beyond.
2025 Profit And Cashflow InflectionA clear 2025 turnaround with positive net income and sizable free cash flow strengthens the company’s ability to self-fund R&D and commercialization. If sustained, this improves capital allocation flexibility, reduces refinancing risk, and supports long-term product investment and scaling of marketed assets.
Conservative Leverage And Larger Equity BaseLow debt-to-equity and a stronger equity base provide financial resilience and optionality. This conservative capital structure supports continued R&D and commercialization spending, buffer against industry cycles, and the ability to pursue partnerships or M&A without stressing leverage metrics.
Bears Say
Multi-year Operating Losses Pre-2025Several consecutive years of negative operating margins before 2025 indicate execution risk and that the recent profit inflection may reflect milestone timing or portfolio mix changes. Sustaining positive operating profitability will require consistent commercial execution across multiple products and expense discipline.
Historically Inconsistent Cash GenerationPrior negative operating and free cash flow years show cash generation volatility. This uneven track record raises funding and planning risks: the company could still need external capital or partnerships during product cycles, complicating long-term reinvestment and creating dependency on non-recurring cash events.
Modest Net Margins And ReturnsDespite strong gross margins, modest net margins and low returns imply limited profitability after SG&A and R&D. This constrains the company’s ability to generate high incremental returns on capital, meaning continued scale or cost efficiency improvements are required to lock in durable bottom-line strength.
Innovent Biologics News
6IB FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was €7.91 and its highest was €11.70 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is €16.79B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 26, 2026 which is in 46 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 26, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of €0.016 by -€0.017.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.14.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,740,920,800 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -€0.001 in its last earnings report, missing expectations of €0.016. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in DE:6IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.71 (39.85% Upside)
€13.71 (39.85% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.65%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
80.58%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
6IB Stock 12 Month Forecast
Average Price Target
€13.71
▲(39.85% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---